[1 Stahl SM. Atypical antipsychotics. Stahl's Essent. Psychopharmacol. Neurosci. Basis Pract. Appl.,. 4`thCambridge: Cambridge University Press, 2013:141–169.]Search in Google Scholar
[2 Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-ofthe-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.10.2147/TCRM.S117321549979028721057]Search in Google Scholar
[3 Kun IZ, Szántó Z, Kun I, et al. Konvencionális és atípusos antipszichotikumok okozta metabolikus szindróma. Orvostudományi Értesítő. 2017;90:7–18.]Search in Google Scholar
[4 Citrome L. The ABC’s of dopamine receptor partial agonists - Aripiprazole, brexpiprazole and cariprazine: The 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69:1211–1220.10.1111/ijcp.1275226477545]Search in Google Scholar
[5 Zimnisky R, Chang G, Gyertyán I, et al. Cariprazine, a dopamine D3-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2013;226:91–100.10.1007/s00213-012-2896-5357227323079899]Search in Google Scholar
[6 Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29:971–985.10.1016/j.euroneuro.2019.06.00831255396]Search in Google Scholar
[7 Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27–35.10.1038/sj.mp.400206617848919]Search in Google Scholar
[8 Horn H, Böhme B, Dietrich L, et al. Endocannabinoids in body weight control. Pharmaceuticals. 2018;11:1–48.10.3390/ph11020055602716229849009]Search in Google Scholar
[9 Bába L-I, Kolcsár M, Hack B, et al. Az endokannabinoid rendszer: receptoroktól a terápiáig (The endocannabinoid system: from the receptors to therapy). Orvostudományi Értesítő. 2019;92:1–14.]Search in Google Scholar
[10 Pertwee RG, Howlett a C, Abood ME, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands : Beyond CB 1 and CB 2. Pharmacol Rev. 2010;62:588–631.10.1124/pr.110.003004299325621079038]Search in Google Scholar
[11 Lu HC, MacKie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516–525.10.1016/j.biopsych.2015.07.028478913626698193]Search in Google Scholar
[12 Faah - Fatty-acid amide hydrolase 1 - Rattus norvegicus (Rat) - Faah gene & protein. Available at https://www.uniprot.org/uniprot/P97612 Accessed August 21, 2020.]Search in Google Scholar
[13 Mgll - Monoglyceride lipase - Rattus norvegicus (Rat) - Mgll gene & protein. Available at https://www.uniprot.org/uniprot/Q8R431 Accessed August 21, 2020.]Search in Google Scholar
[14 Matias I, Belluomo I, Cota D. The Fat Side of the Endocannabinoid System: Role of Endocannabinoids in the Adipocyte. Cannabis Cannabinoid Res. 2016;1:176–185.10.1089/can.2016.0014]Search in Google Scholar
[15 Gasperi V, Fezza F, Pasquariello N, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci. 2007;64:219–229.10.1007/s00018-006-6445-417187172]Search in Google Scholar
[16 Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res. 2006;38:356–358.10.1055/s-2006-92540116718635]Search in Google Scholar
[17 Lazzari P, Serra V, Marcello S, et al. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats. Eur Neuropsychopharmacol. 2017;27:1–12.10.1016/j.euroneuro.2017.03.01028377074]Search in Google Scholar
[18 Liebig M, Gossel M, Pratt J, et al. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. Obesity (Silver Spring). 2010;18:1952–1958.10.1038/oby.2010.1720168311]Search in Google Scholar
[19 Minet-Ringuet J, Even PC, Valet P, et al. Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry. 2007;12:562–571.10.1038/sj.mp.400194817211438]Search in Google Scholar
[20 Bába L-I, Gáll Z, Kolcsár M, et al. Effect on Body Weight and Adipose Tissue by Cariprazine : A Head-to-Head Comparison Study to Olanzapine and Aripiprazole in Rats. Sci Pharm. 2020;88:1–14.10.3390/scipharm88040050]Search in Google Scholar
[21 Weston-Green K, Huang XF, Deng C. Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats. Behav Brain Res. 2011;217:337–346.10.1016/j.bbr.2010.10.03921056063]Search in Google Scholar
[22 De Santis M, Pan B, Lian J, et al. Different effects of Bifeprunox, Aripiprazole, and Haloperidol on body weight gain, food and water intake, and locomotor activity in rats. Pharmacol Biochem Behav. 2014;124:167–173.10.1016/j.pbb.2014.06.00424933333]Search in Google Scholar
[23 Watson DJG, King M V., Gyertyán I, et al. The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. Eur Neuropsychopharmacol. 2016;26:208–224.10.1016/j.euroneuro.2015.12.02026723167]Search in Google Scholar
[24 Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659–661.10.1096/fj.07-9574LSF17942826]Search in Google Scholar
[25 Eaton SL, Roche SL, Llavero Hurtado M, et al. Total Protein Analysis as a Reliable Loading Control for Quantitative Fluorescent Western Blotting. PLoS One. 2013;8:1–9.10.1371/journal.pone.0072457375829924023619]Search in Google Scholar
[26 Moritz CP. Tubulin or Not Tubulin: Heading Toward Total Protein Staining as Loading Control in Western Blots. Proteomics. 2017;17:1–12.10.1002/pmic.20160018928941183]Search in Google Scholar
[27 Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res. 2011;10:1416–1419.10.1021/pr101147621186791]Search in Google Scholar
[28 Skrede S, Martins L, Berge RK, et al. Olanzapine depot formulation in rat: A step forward in modelling antipsychotic-induced metabolic adverse effects. Int J Neuropsychopharmacol. 2014;17:91–104.10.1017/S146114571300086223919889]Search in Google Scholar
[29 Weston-Green K, Huang XF, Deng C. Alterations to melanocortinergic, gabaergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain. PLoS One. 2012;7:1–12.10.1371/journal.pone.0033548330641122438946]Search in Google Scholar
[30 Nisoli E. Endocannabinoids and obesity development - The adipose tissue. Drug Discov Today Dis Mech. 2010;7:e199–e204.10.1016/j.ddmec.2010.12.002]Search in Google Scholar
[31 Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843.10.2337/diabetes.54.10.2838222826816186383]Search in Google Scholar
[32 Tam J, Godlewski G, Earley BJ, et al. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity. Am J Physiol - Endocrinol Metab. 2014;306:E457-468.10.1152/ajpendo.00489.2013392309024381003]Search in Google Scholar
[33 Hu Y, Young AJ, Ehli E a., et al. Metformin and berberine prevent olanzapine-induced weight gain in rats. PLoS One. 2014;9:1–9.]Search in Google Scholar
[34 Skrede S, Fernø J, Vázquez MJ, et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol. 2012;15:163–179.10.1017/S146114571100127121854679]Search in Google Scholar
[35 André A, Gonthier MP. The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol. 2010;42:1788–1801.10.1016/j.biocel.2010.06.00220541029]Search in Google Scholar
[36 Ruiz de Azua I, Lutz B. Multiple endocannabinoid-mediated mechanisms in the regulation of energy homeostasis in brain and peripheral tissues. Cell Mol Life Sci. 2019;76:1341–1363.10.1007/s00018-018-2994-630599065]Search in Google Scholar
[37 Kale VP, Gibbs S, Taylor JA, et al. Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitis. Regul Toxicol Pharmacol. 2019;109:1044983.]Search in Google Scholar
[38 Barutta F, Bellini S, Mastrocola R, et al. Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. Br J Pharmacol. 2018;175:4371–4385.10.1111/bph.14495624013030184259]Search in Google Scholar
[39 Tan S, Liu H, Ke B, et al. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway. Br J Pharmacol. 2020;177:2830–2847.10.1111/bph.15010723606832017042]Search in Google Scholar